Capricor Therapeutics, Inc.

CAPR Healthcare Biotechnology

Capricor Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22.3 million, down 11.5% from fiscal 2023. In the quarter to June 2026, revenue fell 7.92%, EPS fell 22.8% and free cash flow fell 72.9%, each against the same quarter a year earlier.

6.88 0.59 −7.90%
Market cap
$434.3M
P/E
0.0×
Fwd P/E
−13.2×
Dividend yield
—
F-score
4/9
Altman Z
10.32
Beneish M
−2.61
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(107.79%) (46.56%) (56.40%) (73.70%)
ROA
(74.74%) (39.91%) (47.74%) (51.53%)
ROIC
0.00% 0.00% (80,860.30%) (1,019.73%)
Return on Tangible Assets
(97.76%) (34.39%) (41.23%) (52.71%)
Average Days of Receivables
0.00 0.00 — —
Free Cash Flow per Share
0.56 3.85 2.55 2.26
Free Cash Flow
25.42 179.06 146.63 130.91
Capital Expenditures
86.46 248.87 239.27 234.91
Other line items
Cash ROIC
13.93% 28.70% 26.31% 27.04%
Accounts Receivable Turnover
0.00 0.00 — —
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Operating CF/Net income
0.74 0.66 0.81 0.80
Depreciation/Fixed assets
0.16 0.10 0.06 0.02
Capex/Depreciation
49.06 131.75 144.18 278.95
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(1.34) (1.50) (1.61) (1.80)
Capex per Share
1.89 5.35 4.17 4.06
Capex to Sales
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates